top of page


Head of Automation & Screening Technologies

Andrew is a molecular and cell biologist with 17 years of assay development, target validation, and preclinical drug discovery experience in academia and biotech, with particular interest in oncology, neuropsychiatry, and neurodegenerative diseases. Passionate about molecular events that happen at rapid timescales, his past work has helped to enable hight throughput screens for pharmacological modulators of voltage-and ligand-gated ion channels, intracellular transporters, and GPCRs. In addition, he has more recently been involved in the conception, development, and operation of laboratory facilities in early stage small to midsize biotechs in both Boston and San Diego.

bottom of page